Research and Markets: A PharmaVitae Profile of Novo Nordisk
Добавлено: 13.09.2008, 20:59
DUBLIN, Ireland, Sep 11, 2008 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/resea ... nordisk_as) has announced the addition of the "Novo Nordisk A/S: PharmaVitae Profile" company profile to their offering.
This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Novo Nordisk's performance against key rivals in the ethical pharmaceutical sector.
- Analyze how Novo Nordisk's strong position in the diabetes market will position the company within the Big Pharma peer set by 2011.
- Assess the company's highly focused strategy, centred on diabetes treatments, the use of therapeutic proteins and internally sourced R&D productivity.
This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Novo Nordisk's performance against key rivals in the ethical pharmaceutical sector.
- Analyze how Novo Nordisk's strong position in the diabetes market will position the company within the Big Pharma peer set by 2011.
- Assess the company's highly focused strategy, centred on diabetes treatments, the use of therapeutic proteins and internally sourced R&D productivity.